Filing Flows › Editas Medicine (EDIT) › Q2 2026 › vs Q2 2025
Editas Medicine (EDIT) Q2 2026 vs Q2 2025 (year over year)
Editas Medicine's revenue rose $8.3M (+232%) from $3.6M in Q2 2025 to $11.9M in Q2 2026.
Editas Medicine, Q2 2026: revenue $11.9M (+232% year over year), operating margin -156.0%, net loss $18.2M, operating cash flow −$29.6M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $11.9M | $3.6M | $8.3M | +232% |
| Other income, net | $324K | −$1.7M | $2.0M | — |
| Net loss | $18.2M | $53.2M | −$35.0M | -66% |
| Costs & expenses | $30.4M | $56.8M | −$26.4M | -46% |
| Operating costs | $30.4M | $55.1M | −$24.7M | -45% |
| Operating cash sources | $32.2M | $54.7M | −$22.5M | -41% |
| Depreciation | $416K | $1.8M | −$1.4M | -77% |
| Share-based compensation | $2.2M | $2.7M | −$471K | -18% |
| Cash used in operations | $29.6M | $50.2M | −$20.6M | -41% |
| Net loss absorbed | $18.2M | $53.2M | −$35.0M | -66% |
| Working capital & other | $13.9M | $1.5M | $12.5M | +846% |
Questions
How much did Editas Medicine's revenue grow year over year in Q2 2026?
Editas Medicine's revenue rose $8.3M (+232%) from $3.6M in Q2 2025 to $11.9M in Q2 2026.